GlassScriptPhysician profile
Solomon Forouzesh
NPI 1457548133
$94,812.04
in general payments reported to CMS, 2019-2025
49 companies · $5,251 in 2025
The $5,251 reported for 2025 was more than what 86% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50K · 2020: $8,196 · 2021: $7,195 · 2022: $11K · 2023: $6,370 · 2024: $7,150 · 2025: $5,251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Consulting Fee: $1,080 · Education: $284 · Travel and Lodging: $6.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17,401.11 |
| Consulting Fee | $1,080.00 |
| Education | $283.98 |
| Travel and Lodging | $6.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $29,916.79 | 2019-2025 | Enbrel, Otezla, Repatha |
| Celgene Corporation | $23,069.24 | 2019 | |
| Abbvie INC. | $20,567.16 | 2019-2025 | |
| Lilly USA, LLC | $2,255.04 | 2019-2025 | Taltz, Zepbound, Omvoh |
| Janssen Scientific Affairs, LLC | $2,153.41 | 2019-2025 | Tremfya |
| Glaxosmithkline, LLC. | $2,031.55 | 2021-2025 | Benlysta, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $2,029.82 | 2021-2025 | Farxiga, Saphnelo, Airsupra |
| Janssen Biotech, INC. | $1,805.71 | 2019-2025 | Tremfya, Remicade, Stelara |
| Ucb, INC. | $1,507.80 | 2019-2025 | Cimzia, Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,481.50 | 2019-2025 | Ofev, Cyltezo, Spevigo |
| Novartis Pharmaceuticals Corporation | $1,381.93 | 2019-2025 | |
| Pfizer INC. | $1,238.93 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $896.91 | 2020-2025 | Acthar |
| Radius Health, INC. | $751.00 | 2019-2024 | Tymlos |
| Horizon Therapeutics Plc | $528.43 | 2019-2023 | Krystexxa |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $491.11 | 2019-2025 | |
| Novo Nordisk INC | $451.98 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $233.69 | 2019-2022 | |
| Fresenius Kabi USA, LLC | $209.48 | 2023-2025 | Idacio, Adalimumab-Aacf, Tyenne |
| Alexion Pharmaceuticals, INC. | $164.17 | 2023-2025 | Strensiq |
| Exact Sciences Corporation | $153.28 | 2023-2024 | Cologuard Collection Kit |
| Shield Therapeutics INC | $135.46 | 2023-2024 | Accrufer |
| Allergan, INC. | $128.75 | 2020 | |
| Octapharma USA, INC. | $120.11 | 2024-2025 | Octagam Immune Globulin (Human) |
| Mallinckrodt Enterprises LLC | $116.36 | 2019 | |
| Genentech, INC. | $115.54 | 2019 | |
| Sanofi-Aventis U.S. LLC | $99.00 | 2020 | |
| Scilex Pharmaceuticals INC. | $85.22 | 2019-2024 | |
| Aurinia Pharma U.S., INC. | $77.88 | 2023-2025 | Lupkynis |
| Genentech USA, INC. | $75.99 | 2019-2025 | Actemra |
| Merck Sharp & Dohme LLC | $59.98 | 2021-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Sobi, INC | $49.68 | 2019-2023 | |
| Alvogen INC | $47.07 | 2024 | Teriparatide |
| Kyowa Kirin, INC. | $33.63 | 2025 | |
| Sumitomo Pharma America, INC. | $29.63 | 2025 | Gemtesa |
| Sandoz INC. | $28.95 | 2023 | Hyrimoz |
| Biohaven Pharmaceutical Holding Company LTD. | $28.68 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $28.50 | 2023 | Arcalyst |
| Lundbeck LLC | $25.46 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $24.69 | 2024 | Arcalyst |
| Ani Pharmaceuticals, INC. | $24.31 | 2025 | Sovuna |
| Fidia Pharma USA INC. | $24.21 | 2021 | |
| Madrigal Pharmaceuticals | $23.69 | 2024 | Resmetirom |
| Kowa Pharmaceuticals America, INC. | $23.66 | 2022 | |
| Eisai INC. | $20.41 | 2021 | |
| Impel Pharmaceuticals INC. | $19.23 | 2022 | |
| Organon LLC | $18.83 | 2023 | Hadlima |
| Zyla Life Sciences, INC. | $15.75 | 2020 | |
| Medexus Pharma, INC. | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Solomon Forouzesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.